Results 91 to 100 of about 29,527 (256)

Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study.

PLoS ONE, 2019
Recent evidence has raised in discussion the possibility that cannabidiol can act as a negative allosteric modulator of the cannabinoid type 1 receptor. Here we have used computational methods to study the modulation exerted by cannabidiol on the effects
Hery Chung, Angélica Fierro, C David Pessoa-Mahana   +2 more
doaj   +1 more source

The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity

Epilepsia Open, EarlyView.
Abstract Epilepsy comprises a highly heterogeneous group of neurological disorders unified by a persistent predisposition to recurrent seizures, yet driven by remarkably diverse genetic, molecular, and network‐level mechanisms. Advances in genomic technologies have revealed that epilepsy arises from a multilayered genetic architecture encompassing rare
Mohammad Reza Seyedtaghia, Jina Babanzadeh, Marcello Scala, Lorenzo Perilli, Pasquale Striano   +4 more
wiley   +1 more source

Lipid Nanoparticle Formulations for the Skin Delivery of Cannabidiol

Pharmaceutics
Background/Objectives: The aims of this work were to formulate cannabidiol in different lipid carriers for skin delivery after topical application and to study their stability, interaction with the skin, and antibacterial activity.
Maria Natalia Calienni, Mirian Ana Scavone, Ana Paula Sanguinetti, Merlina Corleto, Magalí Rocío Di Meglio, Pablo Raies, Diego Sebastián Cristos, Paulo César Maffia, Jorge Montanari   +8 more
doaj   +1 more source

Rhodium-Catalyzed Asymmetric Addition to 4- or 5‑Carbonyl-cycloenones through Dynamic Kinetic Resolution: Enantioselective Synthesis of (−)-Cannabidiol

The reaction of 4/5-carbonyl-cycloalkenone 1 or its achiral isomer 1′ with organoboronic acid 2 in the presence of a chiral diene (S,S)-Fc-tfb-rhodium catalyst gave disubstituted trans-cycloalkanone 3 with high diastereo- and enantioselectivity.
He Meng (33363), Shufeng Chen (1788964), Jialin Ming (3384194), Wen-Cong Li (15374920)   +3 more
core   +1 more source

Bridging computational and clinical strategies for presurgical identification of epileptogenic networks

Epilepsia Open, EarlyView.
Abstract Objective About one third of epilepsy patients are drug‐resistant. Resective epilepsy surgery remains a key treatment option but depends critically on accurate identification of the seizure onset zone (SOZ), which is still guided mainly by subjective visual inspection of electrophysiological signals.
Tena Dubcek, Debora Ledergerber, Kristina Koenig, Adham Elshahabi, Rafael Polania, Lukas Imbach   +5 more
wiley   +1 more source

Cannabidiol Claims and Misconceptions [PDF]

Trends in Pharmacological Sciences, 2017
Once a widely ignored phytocannabinoid, cannabidiol now attracts great therapeutic interest, especially in epilepsy and cancer. As with many rising trends, various myths and misconceptions have accompanied this heightened public interest and intrigue. This forum article examines and attempts to clarify some areas of contention.
openaire   +2 more sources

Perspectives of Using Cannabidiol in Psychiatry

, 2020
: In the last years there has been an international explosion of debates and studies about using cannabidiol in medicine in a diversity of diseases, from oncological pathologies, autoimmune disorders or neurology but the most promising field, from afar ...
Șchiopu Cristina-Gabriela, Ștefănescu Cristinel   +1 more
core   +1 more source

Response to anti‐seizure medications in children carrying novel or previously reported HCN1 gene variants

Epilepsia Open, EarlyView.
Abstract Objective Variants in the HCN1 gene cause a syndrome of childhood epilepsy and developmental disability with a broad phenotypic range. Many affected children manifest with early infantile epileptic encephalopathy (EIEE) and highly drug‐resistant epilepsy.
Marium N. Khan, Nicholas P. Poolos
wiley   +1 more source

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Frontiers in Pharmacology, 2018
Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not ...
Fernanda F. Peres, Fernanda F. Peres, Alvaro C. Lima, Jaime E. C. Hallak, Jaime E. C. Hallak, José A. Crippa, José A. Crippa, Regina H. Silva, Vanessa C. Abílio, Vanessa C. Abílio   +9 more
doaj   +1 more source

Changes in effectiveness and safety in patients with Lennox–Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open‐label extension study

Epilepsia Open, EarlyView.
This graphical abstract provides an overview of the content from this post hoc analysis describing the trajectories of fenfluramine effectiveness and safety, along with dose changes over time, in patients with Lennox‐Gastaut syndrome. Abstract In the phase 3 randomized controlled trial (RCT; NCT03355209) of fenfluramine in Lennox–Gastaut syndrome (LGS),
Rima Nabbout, Orrin Devinsky, Lieven Lagae, Ingrid E. Scheffer, Renzo Guerrini, Joseph Sullivan, Antonio Gil‐Nagel, Sameer M. Zuberi, Kate Riney, Patrick Healy, Jayne Abraham, Rebecca Zhang Roper, Mélanie Langlois, Amélie Lothe, Kelly G. Knupp   +14 more
wiley   +1 more source